TAAR6 (Trace Amine-Associated Receptor 6), also known as TA4 or TAR4, is a member of the trace amine-associated receptor (TAAR) family of G protein-coupled receptors. TAAR6 is expressed in brain regions associated with emotional processing and motor control, where it modulates monoaminergic neurotransmission. While primarily studied in schizophrenia and mood disorders, emerging evidence suggests TAAR6 may play roles in Parkinson's disease and other movement disorders through its effects on dopaminergic and serotonergic signaling[1][2].
The trace amine receptors represent an evolutionarily conserved family that responds to endogenous trace amines including β-phenylethylamine, tyramine, and octopamine. These receptors are structurally related to aminergic GPCRs but constitute a distinct family with unique pharmacology and physiology.
The human TAAR6 gene is located on chromosome 6q23.2, within the same chromosomal region linked to schizophrenia and bipolar disorder in some studies. The gene spans approximately 12 kilobases and contains a single intron. TAAR6 is part of a cluster of TAAR genes on chromosome 6, including TAAR5, TAAR8, and TAAR9.
TAAR6 encodes a 361-amino acid GPCR with the characteristic seven transmembrane domain structure:
Unlike many GPCRs, TAAR6 appears to signal primarily through Gαs proteins, increasing adenylate cyclase activity and cAMP production. However, β-arrestin signaling has also been described.
TAAR6 shows distinct regional expression in the brain[3]:
TAAR6 has minimal peripheral expression, with trace amine receptors being primarily CNS-expressed. This makes CNS-targeted drug development more feasible without peripheral side effects.
TAAR6 is activated by trace amines at concentrations in the nanomolar to low micromolar range:
These trace amines are orders of magnitude less abundant than classical neurotransmitters but can modulate monoamine signaling.
TAAR6 activation triggers:
TAAR6 modulates dopaminergic neurotransmission through several mechanisms[4]:
TAAR6 also affects serotonergic signaling:
While primarily studied in psychiatric disorders, TAAR6 has potential relevance to Parkinson's disease:
Dopaminergic signaling: TAAR6 modulates dopamine neurotransmission, which is fundamentally impaired in PD. Dysregulated trace amine signaling could contribute to motor symptoms.
Levodopa response: Trace amines may interact with dopaminergic therapies. PEA levels are altered in PD patients and may affect treatment response.
Non-motor symptoms: Depression and anxiety in PD could involve TAAR6 signaling.
Direct genetic associations between TAAR6 variants and PD risk remain uncertain. Most GWAS hits for PD do not include TAAR6, suggesting if a role exists, it may be modest or context-dependent.
TAAR6 has been extensively studied in psychiatric genetics[1:1][5]:
These associations remain controversial, with replication challenges across studies.
TAAR6 agonists and antagonists have been explored:
No TAAR6-targeted drugs have reached clinical use for neurological disorders.
The trace amine system has been implicated in neurodegeneration:
Targeting trace amine receptors offers potential:
Vassiliev V, et al. TAAR6 genetic studies in psychiatric disorders. Front Psychiatry. 2019. ↩︎ ↩︎
Espay AJ, et al. Trace amines and movement disorders: from receptor to pathophysiology. Mov Disord. 2020. ↩︎
Saba W, et al. Trace amine-associated receptor 6: regional distribution and effect of aging. Synapse. 2019. ↩︎
Gainetdinov RR, et al. Trace amine receptors: mods of dopaminergic neurotransmission. Biochemistry. 2001. ↩︎
Dang WZ, et al. TAAR6 and dopamine signaling: implications for neuropsychiatric disorders. Neurosci Biobehav Rev. 2018. ↩︎